Home >Companies >News >Lupin gets USFDA nod for generic diabetes drug

UNITED STATES OF AMERICA : Drug maker Lupin on Tuesday said it has received approval from the US health regulator to market a generic diabetes drug in America.

The Mumbai-based company has received a tentative approval from the US Food and Drug Administration (USFDA) for its Empagliflozin tablets, in strengths of 10 mg and 25 mg, Lupin said in a statement.

The product is a generic version of Boehringer Ingelheim Pharmaceuticals, Inc's Jardiance tablets which are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

As per IQVIA MAT March 2020 data, the drug had an annual sales of around USD 4,368 million in the US.

This story has been published from a wire agency feed without modifications to the text.

Subscribe to newsletters
* Enter a valid email
* Thank you for subscribing to our newsletter.

Click here to read the Mint ePaperLivemint.com is now on Telegram. Join Livemint channel in your Telegram and stay updated

RELATED STORIES
FILE PHOTO: An employee inspects tablets as they move along the production line at a pharmaceutical plant of Lupin, India's No. 2 drugmaker, in Verna, in the western state of Goa, India, June 9, 2017. Picture taken June 9, 2017. REUTERS/Danish Siddiqui/File Photo (REUTERS)

Lupin recalls 35,928 bottles of generic antibiotic drug in the US

1 min read . 02 Aug 2020
In September 2015, Dr Reddy's had signed a commercialisation deal with Australia's Hatchtech for the latter's prescription head lice product Xeglyze Lotion.

Dr Reddy's Laboratories gets USFDA nod for lice treatment lotion

1 min read . 27 Jul 2020
The purpose of the alert, which contained no information about the prevalence of the malware or who has been targeted, is to 'enable network defense and reduce exposure to Chinese government malicious cyber-activity' (Photo: iStock)

US issues alert about malware used by Chinese government

1 min read . 02:52 PM IST
Close

Wait for it…

Log in to our website to save your bookmarks. It'll just take a moment.

Yes, Continue

Your session has expired, please login again.

Yes, Continue
×
My Reads Logout